Pure Global

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia - Trial NCT05405309

Access comprehensive clinical trial information for NCT05405309 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by University of Utah and is currently Recruiting. The study focuses on Chronic Lymphocytic Leukemia. Target enrollment is 39 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05405309
Phase 1/2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05405309
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
A Phase Ib/II Trial of Combination RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

Study Focus

RP-3500 in combination with Olaparib

Interventional

drug

Sponsor & Location

University of Utah

Salt Lake City, United States of America

Timeline & Enrollment

Phase 1/2

Sep 23, 2022

Aug 15, 2027

39 participants

Primary Outcome

Rate of dose-limiting toxicities (DLTs) during the DLT evaluation period,Overall response rate (ORR)

Summary

This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and
 olaparib in R/R CLL patients with DDR deficiencies.

ICD-10 Classifications

Chronic lymphocytic leukaemia of B-cell type
Chronic myelomonocytic leukaemia
Acute myelomonocytic leukaemia
Lymphoid leukaemia
Chronic leukaemia of unspecified cell type

Data Source

ClinicalTrials.gov

NCT05405309

Non-Device Trial